Search
Santa Ana, CA Paid Clinical Trials
A listing of 65 clinical trials in Santa Ana, CA actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 65
There are currently 65 clinical trials in Santa Ana, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Syrentis Clinical Research, Apex Research Institute, GSK Investigational Site and Orange County Retina Medical Group. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Study of TAK-360 in Adults With Idiopathic Hypersomnia
Recruiting
Idiopathic Hypersomnia (IH) is a condition where people feel extremely sleepy during the day, especially in the morning, even if they sleep a lot at night. They may have trouble waking up in the morning, no matter how much they sleep (sometimes more than 11 hours per day), and they can't help feeling tired, even after taking daytime naps. Because of this sleepiness, they may have trouble focusing, thinking clearly, or keeping up with daily activities. They may also have symptoms like dizziness o... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/26/2025
Locations: Takeda Site 10, Santa Ana, California
Conditions: Idiopathic Hypersomnia
A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
Recruiting
EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME)
In the first year, all 3 treatment groups will be treated every 4 weeks with either EYE103 or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm.
Approximately 960 participants will be ente... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: Santa Ana, Santa Ana, California
Conditions: Diabetic Macular Edema (DME)
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
Recruiting
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
06/25/2025
Locations: Southern California Clinical Research, Santa Ana, California
Conditions: Obesity
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
Recruiting
The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo.
Participation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participat... Read More
Gender:
ALL
Ages:
Between 55 years and 80 years
Trial Updated:
06/24/2025
Locations: Syrentis Clinical Research, Santa Ana, California
Conditions: Alzheimer's Disease
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
Recruiting
This prospective longitudinal study will compare incidence rates of Medicare beneficiary surgical and minimally invasive intervention post index procedure, as well as harms associated with the MILD procedure, at 24 months post-treatment with MILD, tested against a control group of similar patients that have had a comparable procedure. This study will start with patients treated with a study procedure having an index date on or after January 1, 2017, and enrollment will continue until stopped by... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: UCI Medical Center- Central Distribution Warehouse - Dyer, Santa Ana, California
Conditions: Lumbar Spinal Stenosis
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
Recruiting
The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants who have obesity or overweight with or without type 2 diabetes. Participants will be screened for about 4 weeks, after which they will enroll into either J2A-MC-GZP1, NCT06972459 (do not have type 2 diabetes) or J2A-MC-GZP2, NCT06972472 (have type 2 diabetes).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Southern California Clinical Research, Santa Ana, California
Conditions: Obesity, Overweight, Type 2 Diabetes
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Recruiting
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.
Gender:
ALL
Ages:
45 years and above
Trial Updated:
06/24/2025
Locations: Southern California Clinical Research, Santa Ana, California
Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD). Approximately 800 additional participants will be enrolled in a 12-month addendum to assess safety of a different titration regimen.
Gender:
ALL
Ages:
Between 65 years and 80 years
Trial Updated:
06/24/2025
Locations: Syrentis Clinical Research, Santa Ana, California
Conditions: Alzheimer Disease
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Recruiting
This study is open to adults who are at least 18 years old and have:
* a confirmed liver disease called non-alcoholic steatohepatitis (NASH)/metabolic-associated steatohepatitis (MASH) and
* moderate or advanced liver fibrosis
People with a history of acute or chronic liver diseases other than MASH or chronic alcohol intake cannot take part in this study. The purpose of this study is to find out whether a medicine called survodutide helps people with MASH and moderate or advanced liver fibrosi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Velocity Clinical Research-Santa Ana-68902, Santa Ana, California
Conditions: Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
Recruiting
The main purpose of this study is to see how orforglipron, compared with placebo, helps reduce body weight in participants with obesity or with overweight and at least one other related health condition (excluding type 2 diabetes). This trial is part of the master protocol study J2A-MC-GZPO.
Participation in the study will last about 18 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Southern California Clinical Research, Santa Ana, California
Conditions: Obesity, Overweight
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
Recruiting
The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with overweight and type 2 diabetes. This trial is part of the master protocol study J2A-MC-GZPO.
Participation in the study will last about 18 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Southern California Clinical Research, Santa Ana, California
Conditions: Obesity, Overweight, Type 2 Diabetes
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
Recruiting
This study will enroll participants with urothelial cancer (UC). UC can include cancer of the bladder, kidney, or the tubes that carry pee through the body (ureter, urethra). This study will try to find out if the drugs disitamab vedotin with pembrolizumab works better than platinum-containing chemotherapy to treat patients with UC. This study will also test what side effects happen when participants take these drugs together. A side effect is anything a drug does to the body besides treating th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: The Oncology Institute of Hope and Innovation, Santa Ana, California
Conditions: Urothelial Carcinoma
1 - 12 of 65